지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 한국약제학회 Journal of Pharmaceutical Investigation Journal of Pharmaceutical Investigation Vol.54 No.1
- 발행연도
- 2024.1
- 수록면
- 99 - 112 (14page)
- DOI
- 10.1007/s40005-023-00651-w
이용수
초록· 키워드
오류제보하기
Purpose The objective of this study was to design a fixed-dose combination (FDC) tablet with minimal interaction of valsartan, amlodipine, rosuvastatin and ezetimibe to improve medication compliance in patients with hypertension and dyslipidemia and to evaluate its feasibility for development through in vitro dissolution test and pharmacokinetic assessment in humans.
Methods The formulation was designed as a bilayer FDC tablet to minimize the interaction of the four drugs based on the results of drug‒drug interaction evaluations in which the drugs were mixed and exposed at 50 °C for 4 weeks. The FDC tablet was then evaluated against the reference listed drug (RLD) products, Exforge® tablet 10/160 mg and Rosuzet® tablet 10/20 mg, through in vitro dissolution studies and in vivo pharmacokinetic studies in humans.
Results The in vitro release profiles of valsartan, rosuvastatin and ezetimibe were similar to those of the RLD products.
Although the Cmax of ezetimibe in the FDC tablet was slightly higher, there were no significant differences in the area under the plasma drug concentration–time curve (AUC). There were also no notable discrepancies in the Cmax and AUC of the other three drugs. Furthermore, the absence of statistically significant variations in the frequency of adverse events and the lack of serious adverse reactions indicate a comparable safety profile between the FDC and RLD tablets.
Conclusion The feasibility of bilayer FDC tablet formulation to improve medication compliance in patients with hypertension and dyslipidemia was demonstrated.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Pharmaceutical application and development of fixed-dose combination: dosage form review
Journal of Pharmaceutical Investigation
2021 .09
-
Moderate-Intensity Rosuvastatin Plus Ezetimibe Versus High-Intensity Rosuvastatin for Target Low-Density Lipoprotein Cholesterol Goal Achievement in Patients With Recent Ischemic Stroke: A Randomized Controlled Trial
대한뇌졸중학회지
2023 .05
-
Additive Beneficial Effects of Valsartan Combined with Rosuvastatin in the Treatment of Hypercholesterolemic Hypertensive Patients
Korean Circulation Journal
2015 .01
-
Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review
Yonsei Medical Journal
2024 .01
-
Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582-9)
Diabetes and Metabolism Journal
2019 .01
-
Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582-9)
Diabetes and Metabolism Journal
2019 .01
-
Combining Ezetimibe and Rosuvastatin: Impacts on Insulin Sensitivity and Vascular Inflammation in Patients with Type 2 Diabetes Mellitus
Diabetes and Metabolism Journal
2024 .01
-
Comparative Efficacy of Rosuvastatin Monotherapy and Rosuvastatin/Ezetimibe Combination Therapy on Insulin Sensitivity and Vascular Inflammatory Response in Patients with Type 2 Diabetes Mellitus
Diabetes and Metabolism Journal
2024 .01
-
Formulation and in vivo imaging evaluation of colonic targeting tablets prepared by a simple dry powder coating technique
Journal of Pharmaceutical Investigation
2020 .01
-
Development of a zero-order kinetics drug release floating tablet with anti?flip-up design fabricated by 3D-printing technique
Journal of Pharmaceutical Investigation
2021 .01
-
Preparation and in vivo characterization of dual release tablet containing sarpogrelate hydrochloride
Journal of Pharmaceutical Investigation
2018 .05
-
Pharmacokinetic Equivalence of the High Dose Strength Fixed-Dose Combination Tablet of Gemigliptin/Metformin Sustained Release (SR) and Individual Component Gemigliptin and Metformin XR Tablets in Healthy Subjects
Journal of Korean Medical Science
2018 .01
-
Orally disintegrating dosage forms
Journal of Pharmaceutical Investigation
2019 .01
-
Comparison of the Effects of Highintensity Statin Therapy with Moderate-Intensity Statin and Ezetimibe Combination Therapy on Major Adverse Cardiovascular Events in Patients with Acute Myocardial Infarction: a Nationwide Cohort Study
지질·동맥경화학회지
2021 .09
-
Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin
지질·동맥경화학회지
2020 .01
-
Bilayer tablets with sustained-release metformin and immediate-release sitagliptin: preparation and in vitro/in vivo evaluation
Journal of Pharmaceutical Investigation
2021 .09
-
Physiologically-based pharmacokinetic predictions of intestinal BCRP-mediated drug interactions of rosuvastatin in Koreans
The Korean Journal of Physiology & Pharmacology
2018 .05
-
Preformulation and evaluation of multi-layer tablets
Journal of Pharmaceutical Investigation
2024 .03
-
Cost-Effectiveness and convenience of MyreptⓇ 500mg tablet in recipients after liver transplantation
한국간담췌외과학회 학술대회지
2015 .09
-
Treatment persistence with a fixed-dose combination of tadalafil (5 mg) and tamsulosin (0.4 mg) and reasons for early discontinuation in patients with benign prostatic hyperplasia and erectile dysfunction
Investigative and Clinical Urology
2020 .01
최근 본 자료
댓글(0)
0